Heart failure & cardiomyopathiesCohort study
Sex Differences in Presentation and Outcomes of Transthyretin Amyloid Cardiomyopathy
- Consecutive prospective patients with confirmed ATTR-CM enrolled in the multicenter Swiss-CARE registry
Authors' conclusion
Women exhibited a higher risk of MACE after diagnosis; however, sex was not an independent predictor of outcomes in multivariable analysis. This disadvantage in women may be partly explained by older age at diagnosis, higher NT-proBNP levels, greater symptom burden, and a higher prevalence of comorbidities, rather than intrinsic sex-specific differences in ATTR-CM progression.
Study context
- Population
- Patients with confirmed transthyretin amyloid cardiomyopathy (ATTR-CM), Swiss-CARE registry, February 2018-March 202552 [9%] women
- Participants
- 567 patients
- Exposure
- Women vs men with ATTR-CM
- Womenn = 52
- Outcome
- First MACE:
- Composite of heart failure hospitalization
- All-cause mortality
Main finding
As reported in the abstract
Hazard ratio
1.86
95% CI 1.13–3.04
P = 0.014
Observational data: associations, not effects.
Further findings
Age at diagnosis · women older
P < 0.001
N-terminal pro-B-type natriuretic peptide · higher in women
P = 0.006
6-minute walking distance · shorter in women
P = 0.001
Tafamidis prescription · less frequent in women
P = 0.004
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Heart failure hospitalizations · within the first 2 years | 2.21 (1.17–4.19) | P = 0.015 | |
| All-cause mortality · trend | 1.82 (0.97–3.43) | P = 0.06 | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | Estimate | P value |
|---|---|---|
| NYHA functional class · higher in women | P < 0.001 |
Original publication
Summarised from the published abstract; every number is checked against it